BiotechTube

ALT-P7 (HM2-MMAE)

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HER2-positive Breast Cancer

Conditions

HER2-positive Breast Cancer

Trial Timeline

Jan 11, 2018 โ†’ Jan 15, 2021

NCT ID
NCT03281824

About ALT-P7 (HM2-MMAE)

ALT-P7 (HM2-MMAE) is a phase 1 stage product being developed by Alteogen for HER2-positive Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03281824. Target conditions include HER2-positive Breast Cancer.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03281824Phase 1Completed

Competing Products

20 competing products in HER2-positive Breast Cancer

See all competitors
ProductCompanyStageHype Score
CT-0508 + PembrolizumabCarisma TherapeuticsPhase 1
25
CT-0525Carisma TherapeuticsPhase 1
25
TrastuzumabCelltrionPhase 3
77
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
77
YH32367YuhanPhase 1/2
41
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
Trastuzumab deruxtecan (T-DXd)Daiichi SankyoPre-clinical
23
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan + Placebo + Taxane + Pertuzumab + TrastuzumabDaiichi SankyoPhase 3
77
DS-8201a + T-DM1Daiichi SankyoPhase 3
77
Pertuzumab + Trastuzumab + eribulinEisaiPhase 2
52
Tucatinib 150 MG + Trastuzumab + CapecitabineBioconPhase 2
52
SHR-A1811 Injection + SHR-A1811 Injection ๏ผ› Pertuzumab Injection + Trastuzumab Injection๏ผ›Pertuzumab Injection ๏ผ› Docetaxel InjectionJiangsu Hengrui MedicinePhase 3
77
PyrotinibJiangsu Hengrui MedicinePre-clinical
23
SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
77
Pyrotinib + Placebo Oral Tablet + Trastuzumab + DocetaxelJiangsu Hengrui MedicinePhase 3
77
SHR-A1811 + Ramucirumab / Paclitaxel/ Docetaxel/ IrinotecanJiangsu Hengrui MedicinePhase 3
77
pyrotinib tablet + Montmorillonite Power + LoperamideJiangsu Hengrui MedicinePhase 1
33

Other Products from Alteogen

ALT02 + EU-licensed Herceptin + US-licensed HerceptinPhase 1
33
ALT-BB4 + 0.9%NaClPhase 1
33
Eylea + ALT-L9Phase 1
33